09/04/2026
CagriSema combines cagrilintide, an amylin analog, with semaglutide, a GLP-1 receptor agonistβtwo medications that work through complementary pathways.
π§ Semaglutide: naturally released by the small intestine, works on GLP-1 pathways involved in appetite, satiety, and slowing gastric emptying.
𧬠Cagrilintide: mimics amylin, a hormone naturally released by the pancreas after eating, helping promote fullness and reduce food intake through a different mechanism.
Two different signals working together to tell your brain: βYouβre full. You donβt need more food.β
The research is getting interesting! In clinical trials, CagriSema has demonstrated meaningful weight loss compared with placebo and its individual components, although it remains investigational and is not currently FDA-approved in the U.S.
β’
β’
β’
πΉππππππ ππππ πππππ²ππππππ‡οΈ
π₯ Send a DM
π Link in bio
π Des Peres Medspa: 314-394-3915
π Dardenne Prairie Medspa: 636-265-0548
π§ Listen to our podcast, Skin Deep with Dr. Amy Miller β link in bio!
St. Louis Medspa, St. Charles Medspa, Skin Rejuvenation, CagriSema, Cagrilintide, GLP1, GLP1 Weight Loss, Semaglutide, Medical Weight Loss